Success Story: EB-1A Approval for a Molecular Biology Expert Advancing Precision Therapeutics
Client’s Testimonial:
"The team is very professional and good. They respond quickly and patiently. I have recommended them to my friend.”
On June 9th, 2026, we received another EB-1A (Alien of Extraordinary Ability) approval for a Research Fellow in the Field of Molecular Biology (Approval Notice).
General Field: Molecular Biology
Position at the Time of Case Filing: Research Fellow
Country of Origin: China
State of Residence at the Time of Filing: Minnesota
Approval Notice Date: June 9th, 2026
Processing Time: 1 month, 5 days (Premium Processing Upgrade Requested)
Case Summary:
Targeted therapies and precision medicine depend on researchers who can connect molecular mechanisms to practical treatment strategies. For one molecular biology expert, this work formed the foundation of a successful I-140 EB-1A petition. The client, who holds a Ph.D. in biomedical sciences, is an established expert in molecular biology, with specialized work in molecular therapeutics, precision medicine, and computational drug discovery. At the time of filing, the client was conducting research at a major U.S. medical research institution, where her work continued to involve gene editing and molecular disease mechanisms.
A Record of Extraordinary Research Contributions
The petition demonstrated that the client’s accomplishments were not limited to a strong academic profile. Instead, it showed a sustained pattern of influence through original research, peer recognition, and independent reliance by other scientists.
- 18 peer-reviewed journal articles, including 8 first-authored articles
- 10 abstracts, including 4 first-authored abstracts
- At least 43 completed peer reviews
- Research funding from the American Heart Association
Expert Support and Independent Recognition
The case was supported by 7 recommendation letters from experts in the field, including independent experts who were familiar with the client’s work through her publications and research influence. These letters helped contextualize the objective evidence and explain why her contributions were significant within molecular biology, molecular therapeutics, precision medicine, and computational drug discovery.
This expert support strengthened the petition by showing that the client’s impact was recognized not only through publications and citations, but also through the judgment of other specialists who could explain how her research advanced the field.
EB-1A Approval and Outlook
This I-140 EB-1A approval reflects the strength of a petition built around sustained acclaim, original contributions, and field-level influence. By organizing the evidence around the client’s research contributions, peer-review activity, publication record, funding support, and expert endorsements, the petition demonstrated that she had risen to the top of her field and that her continued work would benefit the United States.
We congratulate the client on this I-140 EB-1A approval and wish her continued success as she advances molecular therapeutics, precision medicine, and computational drug discovery research in the United States.